MAIA Biotechnology, Inc.

NYSE American MAIA

MAIA Biotechnology, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

MAIA Biotechnology, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NYSE American: MAIA

MAIA Biotechnology, Inc.

CEO	Dr. Vlad Vitoc M.B.A., M.D.
IPO Date	July 28, 2022
Location	United States
Headquarters	444 West Lake Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years